ATM

Serine-protein kinase ATM

900,081 patent compounds predicted against ATM, 515,099 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6627	0.54	6/20
Alpha-Cypermethrin (SCHEMBL21972)	0.58	3/20
Alpha-Cypermethrin (SCHEMBL26435)	0.58	3/20
Alpha-Cypermethrin (SCHEMBL26754)	0.58	3/20
Atrimustine (SCHEMBL8659)	0.56	3/20
SCHEMBL24188	0.53	3/20
SCHEMBL15058	0.53	3/20
Indoxyl Sulfate (SCHEMBL15755)	0.43	3/20
Mitotane (SCHEMBL4040)	1.00	2/20
Mitotane (SCHEMBL4041)	1.00	2/20
SCHEMBL10477	1.00	2/20
SCHEMBL19796	1.00	2/20
Menadione (SCHEMBL25970)	1.00	2/20
Estramustine (SCHEMBL4252)	0.73	2/20
Benzanthrone (SCHEMBL23838)	0.71	2/20
SCHEMBL21295	0.69	2/20
Estramustine (SCHEMBL3974)	0.65	2/20
SCHEMBL11186	0.64	2/20
SCHEMBL21124	0.64	2/20
SCHEMBL10476	0.62	2/20

Germline variants in ATM on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ATM gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ATM by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	PHASE4	UNKNOWN
Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone	PHASE4	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.	PHASE2	WITHDRAWN
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer	PHASE2	COMPLETED
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)	PHASE2	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	PHASE1	RECRUITING
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma	PHASE1	RECRUITING
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer	PHASE1	RECRUITING
M6620 Plus Standard Treatment in Oesophageal and Other Cancer	PHASE1	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients	PHASE1	COMPLETED
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein	nan	COMPLETED
Whole Body MRI for Cancer Surveillance in A-T	nan	COMPLETED
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors	nan	UNKNOWN
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy	nan	WITHDRAWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ATM binder may also engage these)

Protein	Name	Similarity
P97313	—	1.000	P97313 →
Q6PQD5	—	1.000	Q6PQD5 →
Q62388	—	1.000	Q62388 →
Q8H0T4	—	0.999	Q8H0T4 →
Q8QGX4	—	0.999	Q8QGX4 →
Q75QN2	—	0.998	Q75QN2 →
O35870	—	0.997	O35870 →
Q5XI94	—	0.996	Q5XI94 →
E1C231	—	0.996	E1C231 →
Q8BKX6	—	0.996	Q8BKX6 →
E1BGH8	—	0.996	E1BGH8 →
Q3UHQ6	—	0.996	Q3UHQ6 →
Q5R6L2	—	0.995	Q5R6L2 →
SMG1	Serine/threonine-protein kinase SMG1	0.995	landscape →
E1C2Z0	—	0.995	E1C2Z0 →
Q9SUG7	—	0.994	Q9SUG7 →
B1AUR6	—	0.994	B1AUR6 →
Q99698	—	0.994	Q99698 →
Q9DEI1	—	0.994	Q9DEI1 →
Q90WN7	—	0.994	Q90WN7 →
TEX10	Testis-expressed protein 10	0.994	landscape →
PIK3C2A	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	0.994	landscape →
TARBP1	tRNA (guanosine(18)-2'-O)-methyltransferase TARBP1	0.994	landscape →
Q5MNV8	—	0.993	Q5MNV8 →
Q0VF22	—	0.993	Q0VF22 →
Q3TQQ9	—	0.993	Q3TQQ9 →
Q5H9S7	—	0.993	Q5H9S7 →
Q571H0	—	0.993	Q571H0 →
P0DJD0	—	0.993	P0DJD0 →
F6S215	—	0.993	F6S215 →